#1 Clinical Trials Search in Europe

Human Coagulation Factor X

This article discusses clinical trials investigating the use of Human Coagulation Factor X, often as part of prothrombin complex concentrates (PCCs), for reversing anticoagulation and managing major bleeding. These studies aim to evaluate the safety and efficacy of different PCC formulations and dosing strategies in patients taking factor Xa inhibitors who require urgent surgery or experience acute major bleeding.

Table of Contents

What is Human Coagulation Factor X?

Human Coagulation Factor X is a crucial protein involved in the blood clotting process. It is one of several coagulation factors that work together to form blood clots and prevent excessive bleeding. Factor X is often found in combination with other coagulation factors in medical products used to treat or prevent bleeding disorders[1].

Medical Uses

Human Coagulation Factor X, as part of combination products, is used in various medical situations:

  • Reversing the effects of anticoagulant medications (blood thinners)[1]
  • Treating acute major bleeding in patients on anticoagulant therapy[3]
  • Managing bleeding disorders
  • Preventing excessive bleeding during surgeries or invasive procedures[1]

How It Works

Human Coagulation Factor X plays a vital role in the coagulation cascade, which is the series of chemical reactions that lead to blood clot formation. When activated, Factor X (also known as Factor Xa) helps convert prothrombin to thrombin, which then converts fibrinogen to fibrin, forming the basis of a blood clot[1].

In medical products, Factor X is often combined with other coagulation factors (such as Factors II, VII, and IX) to form what’s called a prothrombin complex concentrate (PCC). These products help restore the body’s ability to form blood clots when needed[3].

Administration

Human Coagulation Factor X, as part of combination products, is typically administered through intravenous infusion. The dosage is usually calculated based on the patient’s body weight and the specific medical situation. For example:

  • In some studies, doses ranging from 15 IU/kg to 50 IU/kg have been investigated for reversing anticoagulation effects[3]
  • The maximum daily dose may be up to 2500 IU in certain cases[2]

It’s important to note that these products should only be administered by healthcare professionals in appropriate medical settings.

Ongoing Research

Several clinical trials are currently investigating the use of products containing Human Coagulation Factor X:

  • A study is examining the effectiveness of a product called TAK-330 for reversing anticoagulation in patients needing urgent surgery[1]
  • Another trial is looking at individualized thrombosis prophylaxis in patients undergoing hip or knee replacement surgery[2]
  • A phase 3 trial is investigating the use of OCTAPLEX (a prothrombin complex concentrate) in patients with acute major bleeding who are on anticoagulant therapy[3]

Safety and Side Effects

While products containing Human Coagulation Factor X can be life-saving in certain situations, they also carry potential risks. Some possible side effects and safety considerations include:

  • Risk of thromboembolic events (blood clots)[3]
  • Allergic reactions, particularly in patients with known sensitivities to plasma-derived products[1]
  • Potential for transmitting infectious agents, although modern manufacturing processes have greatly reduced this risk

It’s crucial for patients to discuss the potential risks and benefits with their healthcare providers before receiving these treatments.

Aspect Details
Main Focus Evaluating Human Coagulation Factor X (in PCCs) for anticoagulation reversal and major bleeding management
Target Population Patients on factor Xa inhibitors needing urgent surgery or experiencing major bleeding
Key Medications OCTAPLEX, Cofact, TAK-330 (all containing Human Coagulation Factor X)
Primary Outcomes Hemostatic effectiveness, changes in blood clotting parameters
Safety Monitoring Thromboembolic events, adverse events, mortality
Dosing Strategies Various, including comparison of low-dose (15 IU/kg) vs. high-dose (50 IU/kg)
Trial Designs Randomized, controlled, often multi-center and adaptive

FAQ

  • What is Human Coagulation Factor X? Human Coagulation Factor X is a key protein in the blood clotting process. In these trials, it's often used as part of prothrombin complex concentrates (PCCs), which are medications containing multiple clotting factors to help reverse the effects of blood thinners and manage severe bleeding.
  • Who might benefit from treatments containing Human Coagulation Factor X? Patients who are taking blood thinners (particularly factor Xa inhibitors) and need emergency surgery, or those experiencing major bleeding while on these medications, may benefit from treatments containing Human Coagulation Factor X.
  • How is the effectiveness of these treatments measured in the trials? The effectiveness is primarily measured by assessing hemostasis (the stopping of bleeding). This includes evaluating intraoperative and postoperative bleeding control, changes in blood clotting parameters, and the need for additional blood products or medications to control bleeding.
  • Are there any safety concerns with these treatments? While these treatments can be life-saving, there are potential risks. The trials carefully monitor for adverse events, particularly thromboembolic events (blood clots), which can be a concern when reversing the effects of blood thinners.
  • How quickly do these treatments work? The trials aim to evaluate rapid reversal of anticoagulation. Some studies measure the effects as soon as 1 hour after administration, indicating that these treatments are designed to work quickly in emergency situations.

Ongoing Clinical Trials on Human Coagulation Factor X

  • Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

    Recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +5

  • Study on the Effects of Apixaban Absorption in Patients Undergoing Roux-en-Y Gastric Bypass Surgery

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Croatia Germany Italy Poland Spain

Glossary

  • Anticoagulation: The process of hindering blood clot formation, often achieved through medication (blood thinners).
  • Factor Xa inhibitors: A type of blood thinner that works by blocking a specific clotting factor (Factor Xa) in the blood.
  • Hemostasis: The process that causes bleeding to stop, involving the clotting of blood at the site of an injury.
  • Prothrombin Complex Concentrate (PCC): A medication containing multiple blood clotting factors, used to reverse the effects of blood thinners or treat severe bleeding.
  • Thromboembolic events: Complications involving unwanted blood clots that can block blood vessels, potentially causing serious health issues.
  • Endogenous Thrombin Potential (ETP): A measure of the body's ability to generate thrombin, a key enzyme in blood clotting.
  • Intraoperative: Occurring or performed during a surgical operation.
  • Postoperative: Relating to the period of time immediately following a surgical operation.
  • Haemodynamic compromise: A situation where the heart is unable to maintain adequate blood flow to meet the body's needs.
  • Glasgow Coma Scale: A scoring system used to assess a person's level of consciousness after a brain injury.

References

  1. http://clinicaltrials.eu/trial/study-on-tak-330-for-reversing-anticoagulation-in-patients-on-factor-xa-inhibitors-needing-urgent-surgery/
  2. http://clinicaltrials.eu/trial/study-on-venous-thromboembolism-prevention-with-enoxaparin-sodium-and-drug-combination-for-patients-undergoing-total-hip-or-knee-replacement/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-human-coagulation-factor-ix-and-drug-combination-for-patients-with-major-bleeding-on-factor-xa-inhibitor-therapy/